David A. Siegel Myovant Sciences Ltd. Transaction History

Two Sigma Advisers, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$24.03 - $27.02 $3.18 Million - $3.58 Million	132,500 New	132,500 $3.57 Million
Q2 2021 Aug 16, 2021	SELL	$17.07 - $24.56 $592,329 - $852,232	-34,700 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$20.46 - $25.18 $709,962 - $873,746	34,700 New	34,700 $714,000
Q3 2020 Nov 16, 2020	SELL	$14.05 - $22.6 $358,275 - $576,300	-25,500 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$7.34 - $20.84 $35,966 - $102,116	4,900 Added 23.79%	25,500 $526,000
Q1 2020 May 15, 2020	BUY	$6.55 - $14.76 $134,930 - $304,056	20,600 New	20,600 $156,000
Q4 2019 Feb 14, 2020	SELL	$4.2 - $19.21 $71,400 - $326,570	-17,000 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$5.19 - $9.46 $28,026 - $51,084	-5,400 Reduced 24.11%	17,000 $88,000
Q2 2019 Aug 14, 2019	BUY	$8.69 - $25.0 $194,656 - $560,000	22,400 New	22,400 $203,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.